
PODD
Insulet Corporation
Company Overview
| Mkt Cap | $20.84B | Price | $145.76 |
| Volume | 2.86M | Change | +1.56% |
| P/E Ratio | 84.3 | Open | $144.64 |
| Revenue | $2.7B | Prev Close | $143.52 |
| Net Income | $247.1M | 52W Range | $140.63 - $354.88 |
| Div Yield | N/A | Target | $237.57 |
| Overall | 44 | Value | 35 |
| Quality | 57 | Technical | 40 |
No chart data available
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Latest News
Overvalued? Analysts Say These 3 High P/E Stocks Could Jump 50%+
BTIG Remains a Buy on Insulet (PODD)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (LLY), Insulet (PODD) and Novartis (NVS)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (LLY), Insulet (PODD) and Novartis (NVS)
Raymond James Sticks to Their Buy Rating for Insulet (PODD)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PODD | $145.76 | +1.6% | 2.86M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |